Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193609
Status:
COMPLETED
Last Update Posted:
2013-11-11
First Post:
2005-09-12
Brief Title:
Oxaliplatin and Capecitabine in the Treatment of RelapsedRefractory Carcinoma of Unknown Primary Site
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
A Phase II Trial of Oxaliplatin and Capecitabine in the Treatment of Patients With RelapsedRefractory Carcinoma of Unknown Primary Site
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this phase II trial we will evaluate the feasibility and efficacy of the oxaliplatincapecitabine combination in patients who have had one previous chemotherapy regimen for the treatment of carcinoma of unknown primary site Patients who are relapsed after a previous response to treatment will be eligible as well as those who were refractory to first-line therapy
Detailed Description:
All patients received treatment with oxaliplatin 130mgm2 given intravenously on day 1 of each 21 day cycle Capecitabine 1000mgm2 PO BID was administered on days 1-14 of each cycle
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None